[go: up one dir, main page]

MA52910A - Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs - Google Patents

Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs

Info

Publication number
MA52910A
MA52910A MA052910A MA52910A MA52910A MA 52910 A MA52910 A MA 52910A MA 052910 A MA052910 A MA 052910A MA 52910 A MA52910 A MA 52910A MA 52910 A MA52910 A MA 52910A
Authority
MA
Morocco
Prior art keywords
rsv
prophylaxis
stabilized
fusion protein
soluble
Prior art date
Application number
MA052910A
Other languages
English (en)
Inventor
Anders Krarup
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA52910A publication Critical patent/MA52910A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
MA052910A 2016-04-05 2017-04-04 Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs MA52910A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16163810 2016-04-05

Publications (1)

Publication Number Publication Date
MA52910A true MA52910A (fr) 2021-04-21

Family

ID=55752165

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052910A MA52910A (fr) 2016-04-05 2017-04-04 Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
MA43763A MA43763B1 (fr) 2016-04-05 2017-04-04 Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43763A MA43763B1 (fr) 2016-04-05 2017-04-04 Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs

Country Status (30)

Country Link
US (2) US11155583B2 (fr)
EP (2) EP3439672B1 (fr)
JP (2) JP7088841B2 (fr)
KR (2) KR102506895B1 (fr)
CN (2) CN116063551A (fr)
AU (2) AU2017248021B2 (fr)
BR (1) BR112018070013A2 (fr)
CA (1) CA3018941A1 (fr)
CL (1) CL2018002826A1 (fr)
CY (1) CY1124019T1 (fr)
DK (1) DK3439672T3 (fr)
EA (2) EA202191622A1 (fr)
ES (1) ES2858315T3 (fr)
HR (1) HRP20210113T1 (fr)
HU (1) HUE053027T2 (fr)
IL (2) IL262108B2 (fr)
LT (1) LT3439672T (fr)
MA (2) MA52910A (fr)
MD (1) MD3439672T2 (fr)
MX (2) MX2018012094A (fr)
MY (1) MY190320A (fr)
PE (1) PE20190420A1 (fr)
PH (2) PH12022552125A1 (fr)
PL (1) PL3439672T3 (fr)
PT (1) PT3439672T (fr)
RS (1) RS61456B1 (fr)
SG (1) SG11201807913XA (fr)
SI (1) SI3439672T1 (fr)
SM (1) SMT202100106T1 (fr)
WO (1) WO2017174568A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201902513T4 (tr) * 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
WO2015013551A1 (fr) 2013-07-25 2015-01-29 Marshall Christopher Patrick Protéines f de pré-fusion rsv a stabilisation conformationnelle
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
ES2858315T3 (es) * 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
AU2018249533C1 (en) 2017-04-04 2023-10-12 Institute For Research In Biomedicine Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3758747A1 (fr) 2018-02-28 2021-01-06 University of Washington Vaccins à base de nanostructures auto-assemblables
EP3880243A1 (fr) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Protéines f du vrs sous forme pré-fusion stabilisées
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório
WO2022175479A1 (fr) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2023198815A1 (fr) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Administration séquentielle d'adénovirus
WO2024093554A1 (fr) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 Vaccin sous-unitaire recombinant anti-vrs et son utilisation
CN118725052A (zh) * 2023-03-31 2024-10-01 清华大学 具有稳定融合前构象的呼吸道合胞病毒f蛋白
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2025193857A1 (fr) * 2024-03-12 2025-09-18 Calder Biosciences Inc. Compositions et procédés de vaccin contre le vrs améliorés

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (fr) 1994-06-10 2005-06-29 Genvec, Inc. Système de vecteurs adenoviraux complémentaires et lignées cellulaires correspondantes
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (fr) 1996-04-26 2007-08-14 National Research Council Of Canada Lignees de cellules complements e1 de l'adenovirus
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (fr) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
IL137510A0 (en) 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE421337T1 (de) 1998-11-16 2009-02-15 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6281823B1 (en) 1999-09-21 2001-08-28 Agere Systems Guardian Corp. Direct digital synthesis using a sine weighted DAC
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP2420247A1 (fr) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Formulations d'adénovirus
EP1287159A4 (fr) 2000-05-08 2005-02-09 Davisco Foods Int Inc Traitement enzymatique des proteines de lactoserum permettant d'obtenir des peptides anti-hypertension, produits obtenus et traitement de l'hypertension chez les mammiferes
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469623C (fr) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition pour la conservation de virus
BR0306925A (pt) 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
PT1506287E (pt) 2002-05-14 2007-07-17 Merck & Co Inc Métodos de purificação de adenovírus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2880060C (fr) 2004-01-23 2018-03-13 Agostino Cirillo Porteurs de vaccin adenoviral de chimpanze
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CA2602944C (fr) 2005-04-11 2015-08-11 Crucell Holland B.V. Purification de virus faisant appel a une ultrafiltration
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
WO2007110409A1 (fr) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
AU2009218462B2 (en) 2008-02-29 2015-02-05 Tibotec Pharmaceuticals Method for identifying inhibitors against viruses that use a class I fusion protein
US8225289B2 (en) 2008-03-04 2012-07-17 Wind River Systems, Inc. Method and system for improved tool interaction with a target
WO2010060719A1 (fr) 2008-11-03 2010-06-03 Crucell Holland B.V. Procédé pour la production de vecteurs adénoviraux
RU2531510C2 (ru) * 2008-12-09 2014-10-20 Новавакс, Инк. Модифицированные f протеины sv и способы их применения
CN101464897A (zh) 2009-01-12 2009-06-24 阿里巴巴集团控股有限公司 一种词匹配及信息查询方法及装置
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
UA111141C2 (uk) 2009-06-24 2016-04-11 Глаксосмітклайн Байолоджікалз С.А. Рекомбінантні антигени рсв
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
BR112012003064B8 (pt) 2009-08-13 2021-05-25 Crucell Holland Bv anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
PL2488635T3 (pl) 2009-10-15 2014-04-30 Crucell Holland Bv Proces do oczyszczania adenowirusa z hodowli o dużej gęstości komórek
WO2011050168A2 (fr) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Immunogènes du rsv, anticorps dirigés contre le rsv et compositions associées
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
EP2588124A4 (fr) 2010-07-02 2015-09-09 Ensysce Biosciences Inc Complexes nanotubes monoparoi/siarn et procédés associés
US9139642B2 (en) 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US8317672B2 (en) 2010-11-19 2012-11-27 Kensey Nash Corporation Centrifuge method and apparatus
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
MX2014003777A (es) * 2011-09-30 2015-05-15 Novavax Inc Vacuna de nanoparticulas de proteinas f del rsv recombinantes para el virus respiratorio sincitial.
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405804YA (en) 2012-03-22 2014-10-30 Crucell Holland Bv Vaccine against rsv
WO2014005643A1 (fr) 2012-07-05 2014-01-09 Okairos Ag Nouveaux régimes de primo-vaccination-rappel impliquant des polypeptides immunogènes codés par des polynucléotides
JP6210998B2 (ja) 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
WO2014160463A1 (fr) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines f de rsv pré-fusion et leur utilisation
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US20140271899A1 (en) 2013-03-14 2014-09-18 Peroxyium, Inc., Delaware C Corp. Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceco2 particles via nano-encapsulation and coating
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CN105722856B (zh) * 2013-03-15 2019-04-16 厦门大学 Rsv融合蛋白的表位以及识别其的抗体
US10035842B2 (en) 2013-04-15 2018-07-31 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
CN105189547B (zh) 2013-04-15 2020-01-17 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
TR201902513T4 (tr) * 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015013551A1 (fr) 2013-07-25 2015-01-29 Marshall Christopher Patrick Protéines f de pré-fusion rsv a stabilisation conformationnelle
PL3046536T3 (pl) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Ulepszone formulacje adenowirusów
BR112016028816A8 (pt) 2014-06-13 2021-07-20 Glaxosmithkline Biologicals Sa combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
WO2016040556A1 (fr) 2014-09-12 2016-03-17 Rsv Corporation Virosomes contenant une protéine de fusion de souche de virus respiratoire syncytial de lignée 19 et leurs utilisations
JP6350376B2 (ja) 2015-04-23 2018-07-04 住友金属鉱山株式会社 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2017075125A1 (fr) 2015-10-29 2017-05-04 Emory University Virus rsv chimère, compositions immunogènes et procédés d'utilisation
PT3393512T (pt) 2015-12-23 2026-01-16 Pfizer Inc Mutantes de proteína f de rsv
CA3015570A1 (fr) 2016-03-29 2017-10-05 Peter Kwong Proteines f du vrs modifiees par substitutions et sous conformation de pre-fusion, et leur utilisation
ES2858315T3 (es) * 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
US10522129B2 (en) 2016-10-06 2019-12-31 Gopro, Inc. Active acoustic and vibration noise canceling in waterproof camera
KR102771459B1 (ko) 2016-11-18 2025-02-25 삼성전자주식회사 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법
EP3624844A1 (fr) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Procédés et compositions pour induire une immunité protectrice contre l'infection par le vrs
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
EP3880243A1 (fr) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Protéines f du vrs sous forme pré-fusion stabilisées
BR112021020907A2 (pt) 2019-04-25 2022-04-19 Janssen Vaccines & Prevention Bv Antígenos de influenza recombinantes
EP3969044A1 (fr) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration d'un vaccin contre la grippe saisonnière et vaccin contre le virus respiratoire syncytial à base d'adénovirus
JP2022532742A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório

Also Published As

Publication number Publication date
US20220089652A1 (en) 2022-03-24
MX2018012094A (es) 2019-01-10
EA202191622A1 (ru) 2022-01-31
PE20190420A1 (es) 2019-03-19
JP7362819B2 (ja) 2023-10-17
MX2022015257A (es) 2023-01-11
AU2021209185A1 (en) 2021-08-19
KR20180131584A (ko) 2018-12-10
IL262108A (en) 2018-11-29
HRP20210113T1 (hr) 2021-03-05
JP2019513377A (ja) 2019-05-30
ES2858315T3 (es) 2021-09-30
MY190320A (en) 2022-04-13
AU2017248021B2 (en) 2021-08-12
EP3439672B1 (fr) 2020-11-25
SG11201807913XA (en) 2018-10-30
KR102506895B1 (ko) 2023-03-08
JP7088841B2 (ja) 2022-06-21
RS61456B1 (sr) 2021-03-31
EP3439672A1 (fr) 2019-02-13
EP3808374A1 (fr) 2021-04-21
PT3439672T (pt) 2021-02-24
PH12022552125A1 (en) 2023-04-12
IL262108B (en) 2022-12-01
US20190119330A1 (en) 2019-04-25
DK3439672T3 (da) 2021-02-15
SMT202100106T1 (it) 2021-03-15
MA43763B1 (fr) 2021-03-31
CA3018941A1 (fr) 2017-10-12
CN109069616A (zh) 2018-12-21
AU2017248021A1 (en) 2018-10-04
SI3439672T1 (sl) 2021-02-26
PH12018501962A1 (en) 2019-06-24
PL3439672T3 (pl) 2021-06-14
IL262108B2 (en) 2023-04-01
PH12018501962B1 (en) 2023-09-08
IL291604A (en) 2022-05-01
EA201892251A1 (ru) 2019-03-29
IL291604B2 (en) 2024-02-01
MA43763A (fr) 2019-02-13
JP2022101561A (ja) 2022-07-06
CN116063551A (zh) 2023-05-05
MD3439672T2 (ro) 2021-04-30
US11155583B2 (en) 2021-10-26
BR112018070013A2 (pt) 2019-02-05
EA039095B1 (ru) 2021-12-03
WO2017174568A1 (fr) 2017-10-12
LT3439672T (lt) 2021-01-25
US12234264B2 (en) 2025-02-25
AU2021209185B2 (en) 2023-06-01
CL2018002826A1 (es) 2018-11-16
HUE053027T2 (hu) 2021-06-28
IL291604B1 (en) 2023-10-01
KR20220041966A (ko) 2022-04-01
CY1124019T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
MA52910A (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3704608A4 (fr) Utilisation de réseaux neuronaux dans la création de conceptions d'habillement
EP3505620A4 (fr) Organoïde 2d pour l'infection et la culture de virus de la diarrhée humaine, et utilisation dudit organoïde 2d
EP3714275A4 (fr) Réduction de la présentation d'épitope de jonction pour des néo-antigènes
EP3455263A4 (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3372666A4 (fr) Dispositif et système microfluidique pour l'étude de cultures cellulaires
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3402483A4 (fr) Procédés et compositions pour l'activation de lymphocytes t gamma-delta
EP3672650A4 (fr) Hydrogel pour l'ingénierie tissulaire et la bio-impression
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
EP3423438A4 (fr) Protéines de mouvement de phytovirus et leurs procédés d'utilisation
EP3509594C0 (fr) Inhibiteur d'homologue 2 de lysyl-oxydase pour son employ dans le traitement de la myélofibrose
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP3543240A4 (fr) Inhibiteur de l'urat1 et son utilisation
EP3472260A4 (fr) Compositions et procédés pour la préparation et l'utilisation de matériaux générateurs d'acide
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3448991A4 (fr) Protéase thermostable et procédés pour sa préparation et son utilisation
EP3307239A4 (fr) Formulations pour l'administration dans l'intestin grêle d'antigènes du rsv et des norovirus